New drug targets for depression and anxiety: Is the peptides era arriving?

Research output: Contribution to journalReview articlepeer-review

Abstract

The monoamine theory of mood disorders has dominated psychiatric dogma for nearly 50 years. Recent findings about the role of brain peptides in the regulation of emotions and behavior challenge this over-simplified theory, and are about to open the door for a new era, focused on peptides as putative complementary drug targets in psychiatry. The development of improved animal models for depression would accelerate its arrival.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalDrug Development Research
Volume65
Issue number3
DOIs
StatePublished - Jul 2005

Keywords

  • Angiotensin
  • Animal models
  • Clinical trials
  • Corticotropin-releasing factor type-1 receptor
  • Galanin
  • Melanin-concentrating hormone receptors
  • Monoamines
  • Neuropeptide Y
  • Pharmacogenetics
  • Vasopressin

Fingerprint

Dive into the research topics of 'New drug targets for depression and anxiety: Is the peptides era arriving?'. Together they form a unique fingerprint.

Cite this